Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial investigated a drug called QTI571 and enrolled 17 participants in total. Four participants received a lower dose of 200 mg, and 13 received a higher dose of 400 mg. The trial was primarily looking at unwanted or harmful events (called adverse events), serious adverse events, and deaths that occurred during the study. Secondary measures included changes in how far participants could walk in six minutes, how long it took for their condition to get worse, and how much medical care they used during the trial. The reported data shows that when it came to adverse events (any unwanted health events noted during the trial), all 4 participants in the 200 mg group and all 13 in the 400 mg group experienced at least one. For serious adverse events (those considered more significant or life-threatening), 4 out of 4 in the 200 mg group and 5 out of 13 in the 400 mg group were recorded. Deaths were reported for 2 participants in the 200 mg group and 1 in the 400 mg group. Only 1 participant out of the 17 completed the study, while 16 did not complete it; the reasons for this were not detailed in the submitted data. For the secondary outcome measures — the six-minute walk distance, time to worsening, and medical resource use — the reported data shows that no numerical results were submitted to ClinicalTrials.gov for any of these measures, so those findings cannot be described here. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 26210752) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Pulmonary Hypertension Trial, Terminated
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must have fully completed the previous related clinical trial (called CQTI571A2102), including all final assessments at the end of that study
- You must have met the eligibility requirements for that previous trial and must not have been removed from it for safety reasons
Who may not be able to join:
- People whose heart is not pumping strongly enough (the heart's pumping function, called ejection fraction, is below 45%)
- People with a very low platelet count (platelets are cells that help blood clot), specifically below a certain level that increases bleeding risk
- People with high blood pressure that is not well controlled (top number above 160 or bottom number above 90)
- People with an abnormal heart rhythm reading on an ECG (a specific electrical measurement of the heart called QTcF is too high — above 450 milliseconds for men or 470 milliseconds for women), unless a specific heart condition called right bundle branch block is present (confirm with trial site)
Important: Other eligibility rules not listed here may also apply, so always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
1 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Number of Patients With Adverse Events, Serious Adverse Events and Deaths
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.